Causes of Pancreatitis from GLP-1 Use

Epidemiology and Risk Assessment

• Acute pancreatitis is a rare but established adverse effect linked to GLP-1 receptor agonist use, particularly with exenatide, based on reports to the FDA Adverse Event Reporting System and observational studies 1, 2
• Pancreatitis is a rare adverse effect of GLP-1 receptor agonists, with varying incidence rates reported across studies 1, 2

Mechanism and Risk Factors

• GLP-1 receptors are expressed in pancreatic tissue 3
• Potential alterations in pancreatic enzyme secretion may contribute to GLP-1 RA-induced pancreatitis 2
• Short-acting versus long-acting formulations may increase susceptibility to GLP-1 RA-induced pancreatitis, with short-acting associated with more gastrointestinal side effects 2

Clinical Presentation and Management

• The American Association of Clinical Endocrinologists recommends using GLP-1 RAs with caution in patients with a history of pancreatitis 1, 2
• Starting GLP-1 RAs at low doses and titrating slowly can improve gastrointestinal tolerability 2

Prevention and Monitoring

• Slow dose titration can minimize gastrointestinal side effects and may help prevent pancreatitis 2

GLP-1 Receptor Agonist-Associated Pancreatitis Mechanism and Clinical Evidence

Proposed Mechanistic Pathways

• GLP-1 receptor agonists may promote β-cell proliferation and protect against apoptosis, which could theoretically alter pancreatic architecture with chronic use 4, 5
• Delayed gastric emptying is a primary pharmacodynamic effect of GLP-1 receptor agonists, mediated through vagal nerve pathways and myenteric plexus activation, which could increase intra-abdominal pressure or alter pancreatic secretion patterns 4, 6

Clinical Evidence and Controversy

• The American Association of Clinical Endocrinologists recommends using GLP-1 receptor agonists with caution in patients with a history of pancreatitis 7
• Acute pancreatitis is a rare but established adverse effect, particularly documented with exenatide use in FDA Adverse Event Reporting System data and observational studies 7
• Avoid use in patients with active pancreatitis or strong history of recurrent pancreatitis 7